Keywords
How to Cite
Abstract
Introduction: Livedoid vasculitis manifests exclusively in the lower extremities and mainly in the malleolar region. It can be primary or secondary. When secondary, the disease has a common relationship with thrombophilia and other diseases of the connective tissue. Objective: The present work aims to investigate, through an integrative literature review, the treatment of livedoid vasculitis secondary to thrombophilia. Methods: For the development of this research, the BVS, Scielo and PubMed databases were used. To carry out searches of relevant articles used in the development of the literature review, the following MESH terms were used: (livedoid vasculitis) AND (livedoid vasculitis treatment) OR (thrombophilia) AND (livedoid vasculitis secondary to thrombophilia). The period between 2010 and 2022, was one of the limiting criteria for selecting articles, which could be in Portuguese, Spanish or English. Twenty one articles were selected for analysis of this research. Results: Among the authors of the 21 analyzed articles, it showed that the use of low molecular weight Heparin and Direct Oral Anticoagulants were the most prevalent therapies in cases of Livedoid Vasculitis, however this does not indicate that the other therapies are ineffective. Since each clinical picture has its specificities. Conclusion: The treatment options for secondary livedoid vasculitis are varied, and the physician must evaluate and individualize treatment for each patient. Among the known and relevant treatments are: therapy with low molecular weight heparin, therapy with direct oral anticoagulants, intravenous immunoglobulins, therapy with the use of Fenprocoumon and warfarin, and hyperbaric oxygen therapy. New studies comparing the different treatments for livedoid vasculitis secondary to thrombophilia are needed, especially in cases associated with Antiphospholipid Antibody Syndrome.
References
Kerk N, Goerge T. Livedoid vasculopathy: a thrombotic disease. Vasa. 2013;42(5):317-22.
Santos RP, Ferreira O, Brito C. Vasculopatia livedóide: uma revisão de 5 casos clínicos. J Port Soc Dermatol Venereol. 2018;76(3):287-94.
Santos LML, Albuquerque CB, Castañon MCMN, Bonfante HLM, Bonfante HL. Vasculopatia livedoide: desafio diagnóstico e evolução favorável após 5 anos de tratamento com rivaroxabana. Rev Med Minas Gerais. 2020;30:e-E0027.
Abbade LPF, Frade MAC, Pegas JRP, Dadalti‐Granja P, Garcia LC, Bueno Filho R, et al. Consenso sobre diagnóstico e tratamento das úlceras crônicas de perna - Sociedade Brasileira de Dermatologia. An Bras Dermatol. 2020;95(S1):1-18.
Bezerra AS, Andrade AAAJ, Polimanti AC, Fürst RVC, Criado PR, Corrêa JA. Livedoid vasculopathy: diagnosis and treatment in pregnant women. J Vasc Bras. 2020;19:e20190093.
Espinel DPGS. Análise dos níveis séricos e expressão tecidual cutânea da lipoproteína (a) em doentes com vasculopatia livedoide [tese]. São Paulo: Universidade de São Paulo; 2017.
Bertequini C, Pozo MM. Mononeuropatia múltipla por vasculite livedoide: relato de caso. Rev Corpus Hippocrat. 2020;2(1).
Micieli R, Alavi A. Treatment for livedoid vasculopathy: a systematic review. JAMA dermatology. 2018;154(2):193-202.
Di Giacomo TB, Hussein TP, Souza DG, Criado PR. Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs: a prospective study. J Eur Acad Dermatol Venereol. 2010;24(11):1340-6.
Bardin L. Análise de conteúdo. São Paulo: Edições 70; 2011. 229p.
Araujo RS, Magnagnagno OA, Campagnolo OA. Vasculite livedoide: relato de caso. Fag J Health. 2019;1(4):119-23.
Goslan CJ, Baretta GAP, Souza HGP, Orsi BZ, Zanoni ECA, Lopes MAG, et al. Profilaxia da trombose venosa profunda em cirurgia bariátrica: estudo comparativo com doses diferentes de heparina de baixo peso molecular. J Vasc Bras. 2018;17(1):26-33.
Nobrega CMM, Palitot JMG, Albuquerque EMA, Costa MASF, Domingues RB. Tratamento do tromboembolismo venoso em neonatos e crianças. R Multidiscip Saúde. 2020;1(3):82.
Fernandes CJCS, Alves Júnior JL, Gavilanes F, Prada LF, Morinaga LK, Souza R. Os novos anticoagulantes no tratamento do tromboembolismo venoso. J Bras Pneumol. 2016;42(2):146-54.
Romero PS. Subanálise do Vascor-Score na predição de risco de complicações vasculares em pacientes submetidos a procedimentos cardiológicos percutâneos em dois centros de referência [dissertação]. Porto Alegre: Universidade Federal do Rio Grande do Sul; 2017.
Ardila JPM. Vasculitis livedoide [dissertação]. Riobamba: Escuela Superior Politécnica de Chimborazo; 2019.
Morita TCAB, Trés GFS, Criado RFJ, Sotto MN, Criado PR. Atualização em vasculites: visão geral e pontos relevantes dermatológicos para o diagnóstico clínico e histopatológico - Parte I. An Bras Dermatol. 2020;95(3):355-71.
Criado PR, Espinell DPS, Barreto P, Di Giacomo THB, Sotto MN. Lipoprotein (a) and livedoid vasculopathy: a new thrombophilic factor? Med Hypotheses. 2015;85(5):670-4.
Aldehaim AY, Alarfaj AS. Livedoid vasculitis in a patient with sjogren syndrome successfully treated with methotrexate. Clin Med Insights Case Rep. 2022;15:11795476221088489.
Herrera-Sánchez A, Madriagal-Alvarado MJ, Moncayo G, Verdini F. Medium-pressure hyperbaric oxygen therapy for livedoid vasculopathy. Medicina (B Aires). 2022;82(4):613-6.
Ramphall S, Rijal S, Prakash V, Ekladios H, Saju JM, Mandal N, et al. Comparative efficacy of rivaroxaban and immunoglobulin therapy in the treatment of livedoid vasculopathy: a systematic review. Cureus. 2022;14(8):e28485.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Ellen Vilanova Alves Garcia, Ana Luiza de Almeida Leal, Paula Fernanda da Silva Souza, Erica Patrício Nardino
